The US Food and Drug Administration approved Gilead Sciences' new drug, lenacapavir, a twice-yearly injection, for preventing HIV infection in adults and adolescents.
The approved drug, Lenacapavir, developed by Gilead Sciences, will be marketed under the brand name Yeztugo.
It is a twice-yearly injection designed to prevent HIV infection in both adults and adolescents, offering an alternative to daily oral pills.
Lenacapavir belongs to a new class of antiretrovirals known as capsid inhibitors. In large-scale clinical trials conducted last year, the drug demonstrated nearly 100 per cent effectiveness in preventing HIV transmission, raising hopes for a breakthrough in curbing the virus’s spread.
Gilead was initially under pressure from activists and advocates to license its experimental outcomes to six generic drug manufacturers.
